BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst John McNulty has maintained an 'Outperform' rating on Chemours (NYSE:CC) but lowered the price target from $45 to $39.
October 30, 2023 | 2:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
BMO Capital has maintained an 'Outperform' rating on Chemours but lowered the price target from $45 to $39.
The news is directly about Chemours and is likely to impact its stock. While the 'Outperform' rating is positive, the lowering of the price target may have a neutralizing effect on the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100